Comparing bioAffinity Technologies (BIAF) and Its Peers

bioAffinity Technologies (NASDAQ:BIAF) is one of 36 public companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare bioAffinity Technologies to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, profitability, earnings and analyst recommendations.

Volatility & Risk

bioAffinity Technologies has a beta of 3.93, suggesting that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ rivals have a beta of 6.29, suggesting that their average share price is 529% more volatile than the S&P 500.

Profitability

This table compares bioAffinity Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-277.19%	-24.82%	-13.79%

Earnings & Valuation

This table compares bioAffinity Technologies and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.63
bioAffinity Technologies Competitors	$1.50 billion	$86.53 million	6.82

bioAffinity Technologies’ rivals have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for bioAffinity Technologies and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	36	654	1083	30	2.61

As a group, “Commercial physical research” companies have a potential upside of 15.05%. Given bioAffinity Technologies’ rivals higher possible upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 17.2% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

bioAffinity Technologies rivals beat bioAffinity Technologies on 9 of the 10 factors compared.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.